New hope for hard-to-treat breast cancer: immune-boosting drug plus chemo shows promise
NCT ID NCT07540533
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy can help shrink tumors or slow disease in people with advanced HER2-negative breast cancer. About 92 adults whose cancer has worsened after prior treatments will receive the combination. The goal is to see how many patients respond and how long the benefit lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE-RECEPTOR-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450003, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact